MacroGenics Historical Income Statement

MGNX Stock

USD 3.64 0.24 7.06%

Historical analysis of MacroGenics income statement accounts such as Total Revenue of 89.7 M can show how well MacroGenics performed in making a profits. Evaluating MacroGenics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of MacroGenics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining MacroGenics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MacroGenics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

About MacroGenics Income Statement Analysis

MacroGenics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to MacroGenics shareholders. The income statement also shows MacroGenics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

MacroGenics Income Statement Chart

At this time, MacroGenics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 89.7 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 7.3 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Research Development

Total Revenue

Total revenue comprises all receipts MacroGenics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of MacroGenics. It is also known as MacroGenics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from MacroGenics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into MacroGenics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.At this time, MacroGenics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 89.7 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 7.3 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	275.8M	266.0M	217.2M	181.0M
Cost Of Revenue	2.7M	7.4M	8.2M	7.8M

Total Operating Expenses Cost Of Revenue

MacroGenics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Operating Income Net Other	Reconciled Depreciation	Net Interest Income	Interest Income
Depreciation And Amortization		0.95	0.48	0.01	0.97	-0.86	-0.76	0.97	-0.73	0.2	0.97	-0.76	0.24	-0.75	-0.38	-0.75	0.74	0.84	0.23	0.23
Selling General Administrative	0.95		0.43	0.04	0.98	-0.89	-0.74	0.96	-0.71	-0.02	0.98	-0.75	0.3	-0.74	-0.24	-0.73	0.67	0.83	0.31	0.3
Total Revenue	0.48	0.43		0.64	0.47	-0.09	-0.15	0.47	-0.12	0.07	0.47	-0.16	-0.07	-0.16	-0.08	-0.14	0.68	0.31	-0.01	-0.02
Gross Profit	0.01	0.04	0.64		0.03	0.24	0.24	0.01	0.25	-0.26	0.02	0.18	-0.11	0.19	0.47	0.18	0.2	-0.09	0.01	0.01
Other Operating Expenses	0.97	0.98	0.47	0.03		-0.9	-0.79	1.0	-0.76	0.15	1.0	-0.79	0.24	-0.79	-0.3	-0.78	0.68	0.81	0.25	0.24
Operating Income	-0.86	-0.89	-0.09	0.24	-0.9		0.75	-0.9	0.73	-0.07	-0.9	0.76	-0.45	0.76	0.21	0.75	-0.52	-0.81	-0.42	-0.42
Ebit	-0.76	-0.74	-0.15	0.24	-0.79	0.75		-0.81	1.0	-0.39	-0.8	1.0	0.25	1.0	0.64	1.0	-0.21	-0.63	0.27	0.28
Research Development	0.97	0.96	0.47	0.01	1.0	-0.9	-0.81		-0.79	0.23	1.0	-0.82	0.21	-0.82	-0.35	-0.8	0.68	0.8	0.2	0.2
Ebitda	-0.73	-0.71	-0.12	0.25	-0.76	0.73	1.0	-0.79		-0.4	-0.77	1.0	0.28	1.0	0.65	1.0	-0.17	-0.6	0.31	0.31
Cost Of Revenue	0.2	-0.02	0.07	-0.26	0.15	-0.07	-0.39	0.23	-0.4		0.17	-0.36	-0.4	-0.37	-0.63	-0.36	0.07	-0.08	-0.47	-0.47
Total Operating Expenses	0.97	0.98	0.47	0.02	1.0	-0.9	-0.8	1.0	-0.77	0.17		-0.8	0.23	-0.8	-0.32	-0.79	0.68	0.81	0.23	0.22
Income Before Tax	-0.76	-0.75	-0.16	0.18	-0.79	0.76	1.0	-0.82	1.0	-0.36	-0.8		0.25	1.0	0.6	1.0	-0.2	-0.63	0.26	0.27
Total Other Income Expense Net	0.24	0.3	-0.07	-0.11	0.24	-0.45	0.25	0.21	0.28	-0.4	0.23	0.25		0.25	0.51	0.26	0.49	0.35	0.99	0.99
Net Income	-0.75	-0.74	-0.16	0.19	-0.79	0.76	1.0	-0.82	1.0	-0.37	-0.8	1.0	0.25		0.59	1.0	-0.2	-0.62	0.26	0.27
Income Tax Expense	-0.38	-0.24	-0.08	0.47	-0.3	0.21	0.64	-0.35	0.65	-0.63	-0.32	0.6	0.51	0.59		0.6	-0.12	-0.23	0.6	0.6
Net Income From Continuing Ops	-0.75	-0.73	-0.14	0.18	-0.78	0.75	1.0	-0.8	1.0	-0.36	-0.79	1.0	0.26	1.0	0.6		-0.18	-0.62	0.28	0.28
Non Operating Income Net Other	0.74	0.67	0.68	0.2	0.68	-0.52	-0.21	0.68	-0.17	0.07	0.68	-0.2	0.49	-0.2	-0.12	-0.18		0.54	0.49	0.48
Reconciled Depreciation	0.84	0.83	0.31	-0.09	0.81	-0.81	-0.63	0.8	-0.6	-0.08	0.81	-0.63	0.35	-0.62	-0.23	-0.62	0.54		0.36	0.35
Net Interest Income	0.23	0.31	-0.01	0.01	0.25	-0.42	0.27	0.2	0.31	-0.47	0.23	0.26	0.99	0.26	0.6	0.28	0.49	0.36		1.0
Interest Income	0.23	0.3	-0.02	0.01	0.24	-0.42	0.28	0.2	0.31	-0.47	0.22	0.27	0.99	0.27	0.6	0.28	0.48	0.35	1.0

Click cells to compare fundamentals

MacroGenics Account Relationship Matchups

MacroGenics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	10.8M	12.0M	11.3M	11.9M	9.6M	7.3M
Selling General Administrative	46.1M	42.7M	63.0M	58.9M	52.2M	37.0M
Total Revenue	62.0M	97.8M	75.6M	151.9M	58.7M	89.7M
Gross Profit	(133.3M)	97.8M	73.0M	144.6M	50.5M	71.6M
Other Operating Expenses	239.2M	228.8M	278.4M	273.4M	227.0M	182.7M
Operating Income	(177.2M)	(131.1M)	(202.8M)	(121.4M)	(168.2M)	(159.8M)
Ebit	(177.2M)	(131.1M)	(202.8M)	(121.4M)	(7.6M)	(8.0M)
Research Development	195.3M	193.2M	214.6M	207.0M	166.6M	147.1M
Ebitda	(166.3M)	(119.1M)	(191.5M)	(109.6M)	2.0M	2.1M
Cost Of Revenue	195.3M	193.2M	2.7M	7.4M	8.2M	7.8M
Total Operating Expenses	239.2M	228.8M	275.8M	266.0M	217.2M	181.0M
Income Before Tax	(151.8M)	(129.7M)	(202.1M)	(119.8M)	(9.1M)	(9.5M)
Total Other Income Expense Net	25.4M	1.3M	680K	1.7M	159.2M	167.1M
Net Income Applicable To Common Shares	(151.8M)	(129.7M)	(202.1M)	(119.8M)	(107.8M)	(113.2M)
Net Income	(151.8M)	(117.8M)	(190.9M)	(120.0M)	(9.1M)	(9.5M)
Income Tax Expense	(25.4M)	(12.0M)	(11.3M)	263K	9.5M	10.0M
Net Income From Continuing Ops	(151.8M)	(129.7M)	(202.1M)	(119.8M)	(9.1M)	(9.5M)
Reconciled Depreciation	10.8M	12.0M	11.3M	11.9M	9.6M	11.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MacroGenics Historical Income Statement

About MacroGenics Income Statement Analysis

MacroGenics Income Statement Chart

Total Revenue

Other Operating Expenses

MacroGenics income statement Correlations

MacroGenics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MacroGenics income statement Accounts

Also Currently Popular

Additional Tools for MacroGenics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Ebit
Research Development	Ebitda
Cost Of Revenue	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Net Income From Continuing Ops
Non Operating Income Net Other	Reconciled Depreciation
Net Interest Income	Interest Income

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Ebit

Total Operating Expenses	- 0.9	Operating Income
Research Development	- 0.9	Operating Income
Operating Income	- 0.9	Other Operating Expenses
Operating Income	- 0.89	Selling General Administrative
Operating Income	- 0.86	Depreciation And Amortization
Net Income	- 0.82	Research Development